Skip to content

The Prevalence of Prediabetes in Primary Care Medicine in Tunisia

The Prevalence of Prediabetes in Primary Care Medicine in Tunisia. a National Descriptive Cross-Sectional Study

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06825533
Acronym
TUN-PREDIAB
Enrollment
5000
Registered
2025-02-13
Start date
2025-04-21
Completion date
2025-08-21
Last updated
2025-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prediabetes

Keywords

Prediabetes, STMGF, Survey

Brief summary

The study is national, observational and cross-sectional and aims to estimate the prevalence of prediabetes in primary care in Tunisia.

Detailed description

TN-PREDIAB is a Tunisian, descriptive, non-interventional, multicenter and cross-sectional clinical study performed in primary care facilities, of both public and private sectors. The study will screen ambulatory patients for at least 4 months to estimate the prevalence of prediabetes among enrolled subjects. The objectives of the study are: * Primary objective: to estimate the overall prevalence of prediabetes among Tunisian population * Secondary objective: * Describe the clinical and epidemiological profile of prediabetic subjects * Describe nutritional factors associated with prediabetes A Scientific Committee validates the scientific writing, a Steering Committee supervises the clinical operations of the project. Collected data are managed by the DACIMA Clinical Suite®, the electronic data capture platform which complies with the FDA 21 CFR part 11 requirements (Food and Drug Administration 21 Code of Federal Regulations part 11), the HIPAA specifications (Health Insurance Portability and Accountability Act), and the ICH standards (International Conference on Harmonisation).

Interventions

DIAGNOSTIC_TESTFasting blood sugar level

Assess the level of Blood sugar level in fasting conditions at inclusion

DIAGNOSTIC_TESTGlycated hemoglobin

Assess the level of glycated hemoglobin at inclusion

Sponsors

Société Tunisienne de Médecine Générale et de Médecine de Famille
CollaboratorUNKNOWN
Dacima Consulting
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Ambulatory patient consulting in primary care in a public or private structure

Exclusion criteria

* Known diabetes * Concomitant medication that may influence blood sugar (corticosteroids, metformin, GLP1 analogues, SGLT2 inhibitor) * Severe, acute or chronic comorbidity (end-stage renal failure, severe liver disease, heart failure) * Severe anemia * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
PrediabetesAt inclusionPercentage of prediabetic patients discovered at inclusion

Contacts

Primary ContactMohamed Haithen Ben Haj Salah, MD
haithembelhaj@yahoo.fr+216 52 988 183
Backup ContactHabib Jerbi, MD
drjerbi@yahoo.fr+216 98 401 188

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026